Prosecution Insights
Last updated: October 24, 2026
Application No. 17/747,397

METHODS OF EVALUATING BRAIN INJURY IN A PEDIATRIC SUBJECT

Final Rejection §112§DOUBLEPATENT
Filed
May 18, 2022
Priority
May 18, 2021 — provisional 63/189,757 +1 more
Examiner
CHERNYSHEV, OLGA N
Art Unit
1675
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Abbott Laboratories
OA Round
4 (Final)
54%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
525 granted / 963 resolved
-5.5% vs TC avg
Strong +34% interview lift
Without
With
+34.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
63 currently pending
Career history
1014
Total Applications
across all art units

Statute-Specific Performance

§101
15.7%
-24.3% vs TC avg
§103
8.5%
-31.5% vs TC avg
§102
11.6%
-28.4% vs TC avg
§112
47.2%
+7.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 963 resolved cases

Office Action

§112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Response to Amendment 1. Claims 1, 2, 14, 15 and 22 have been amended and claims 23 and 28 canceled as requested in the amendment filed on September 10, 2026. Following the amendment, claims 1, 2, 7, 8, 13-15, 21, 22, 24, 26, 29, 31, 33 and 34 are pending in the instant application. 2. Claims 1, 2, 7, 8, 13-15, 21, 22, 24, 26, 29, 31, 33 and 34 are under examination in the instant office action. 3. Any objection or rejection of record, which is not expressly repeated in this action has been overcome by Applicant’s response and withdrawn. 4. Applicant’s arguments filed on September 10, 2026, have been fully considered but they are not deemed to be persuasive for the reasons set forth below. New grounds of rejection necessitated by Applicant’s amendment are set forth below as well. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 5. Claims 14, 15 and 21, as amended, are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. 6. Claim 14, as currently presented, is vague and ambiguous with respect to section c). Briefly, the text of section c) encompasses determination “based on the level(s) measured in step a) satisfying the condition(s) recited in step b),” and it is not obvious what stands for “based on” step a), wherein step a) is limited to performing an assay on a sample. It is further not clear what stands for “conditions” to be satisfied of step b), which is a head CT scan. Applicant is advised that if the claim intends to recite that the specific levels of GFAP and UCH-L1 stand for mTBI then that is what the claim should recite to avoid ambiguity of interpretation. Further, step c) indicates the diagnosis of mTBI as “more likely than not,” while step d) recites “the subject determined as having sustained a mild TBI,” and the connection between steps c) and d) is not clear because step c) produces only likelihood and not determination of mTBI diagnosis. 7. Claims 15 and 21 are indefinite for being dependent from indefinite claim(s). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 8. Claims 1, 2, 7, 8, 13-15, 21, 22, 24, 26, 29, 31, 33 and 34 stand rejected on the ground of nonstatutory double patenting as being unpatentable over claims of the following issued US Patents: U.S. Patent No. 10,849,548; 10,866,251;10,877,038; 10,877,048; 11,016,092; 11,016,105; 11,022,617; 11,931,161; 12,085,567; 12,092,647; 12,099,069; 12,105,098; 12,105,100 and 12,163,958 for reasons of record in section 8 of Paper mailed on May 09, 2025, section 10 of Paper mailed on January 28, 2026 and section 13 of Paper mailed on June 12, 2026. Conclusion 9. No claim is allowed. 10. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to OLGA N CHERNYSHEV whose telephone number is (571)272-0870. The examiner can normally be reached 9AM to 5:30PM, Monday to Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Stucker can be reached at (571)272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /OLGA N CHERNYSHEV/ Primary Examiner, Art Unit 1675 September 30, 2026
Read full office action

Prosecution Timeline

Show 1 earlier event
May 09, 2025
Non-Final Rejection mailed — §112, §DOUBLEPATENT
Nov 07, 2025
Response Filed
Jan 28, 2026
Final Rejection mailed — §112, §DOUBLEPATENT
Apr 28, 2026
Request for Continued Examination
Apr 29, 2026
Response after Non-Final Action
Jun 12, 2026
Non-Final Rejection mailed — §112, §DOUBLEPATENT
Sep 10, 2026
Response Filed
Oct 08, 2026
Final Rejection mailed — §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12716893
MATERIALS AND METHODS FOR DETECTING AND TREATING AUTOIMMUNE MOVEMENT DISORDERS
4y 10m to grant Granted Aug 25, 2026
Patent 12710431
DIAGNOSTIC FOR CHILDHOOD RISK OF AUTISM SPECTRUM DISORDER
4y 10m to grant Granted Aug 18, 2026
Patent 12710433
Diagnosing a Disease Associated with Synaptic Degeneration using an Elisa for Determining a Beta-Synuclein Concentration in CSF
3y 12m to grant Granted Aug 18, 2026
Patent 12708657
PHARMACEUTICAL COMPOSITION FOR TREATING DEGENERATIVE BRAIN DISEASE, INCLUDING GLYCINE TRANSPORTER AS ACTIVE INGREDIENT
3y 10m to grant Granted Aug 18, 2026
Patent 12698344
ANTI-IDE ANTIBODIES AND USES OF SAME
4y 0m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
54%
Grant Probability
88%
With Interview (+34.0%)
2y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 963 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month